CONMED CNMD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 55.2%-1.0pp | 54.6%-1.5pp | 54.2%-1.4pp | 56.1%+0.7pp | 56.1%+1.2pp | |
| Operating margin | 8.2%-5.6pp | 7.5%-7.9pp | 8.8%-6.6pp | 13%+0.2pp | 13.8%+2.4pp | |
| Net margin | 4%-5.0pp | 3.4%-6.7pp | 4.8%-5.5pp | 8.3%+0.6pp | 9%+2.5pp | |
| EBITDA margin | 12%-5.7pp | 11.3%-8.0pp | 12.7%-6.7pp | 16.9%+0.2pp | 17.7%+2.3pp | |
| Free cash flow margin | 9%-3.5pp | 11%-0.8pp | 11.1%-1.8pp | 11.2%-1.3pp | 12.5%+1.3pp | |
| Returns | ||||||
| Return on equity | 5.5%-7.5pp | 4.7%-10.0pp | 6.6%-8.6pp | 11.7%-0.2pp | 13%+2.7pp | |
| Return on assets | 2.4%-2.8pp | 2%-3.7pp | 2.8%-2.9pp | 4.8%+0.5pp | 5.2%+1.6pp | |
| Return on invested capital | 4.1%-4.0pp | 3.6%-5.2pp | 4.8%-4.0pp | 7.5%+0.5pp | 8.1%+1.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | |
| Inventory turnover | 1.7×0.0× | 1.8×+0.1× | 1.7×0.0× | 1.7×-0.1× | 1.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.3×0.0× | 2.1×-0.2× | 2.1×-0.2× | 2.2×-0.1× | 2.3×+0.1× | |
| Quick ratio | 1×0.0× | 1×0.0× | 0.9×-0.1× | 1×-0.1× | 1×-0.1× | |
| Cash ratio | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.8×-0.1× | 0.9×-0.1× | 0.8×-0.2× | 0.9×-0.2× | 0.9×-0.2× | |
| Debt-to-assets | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Net debt / EBITDA | 5×+1.3× | 5.5×+1.8× | 4.8×+1.2× | 3.8×-0.6× | 3.7×-1.3× | |
| Interest coverage | 3.8×-1.3× | 3.3×-2.1× | 3.6×-1.6× | 5×+0.8× | 5×+1.4× | |
| Per Share | ||||||
| Book value per share | $33.23+5.9% | $33.17+7.3% | $32.47+8.3% | $32.29+13.9% | $31.38+14.8% | |
| Valuation | ||||||
| Market capitalization | $1.04B-35.6% | $1.26B-40.5% | $1.46B-34.3% | $1.63B-23.4% | $1.87B-24.3% | |
| Enterprise value | $1.87B-24.5% | $2.11B-30.7% | $2.27B-27.2% | $2.49B-19.2% | $2.73B-20.4% | |
| Price / earnings | 19×+5.4× | 26.7×+10.8× | 22.7×+5.9× | 14.8×-6.8× | 15.7×-14.2× | |
| Price / sales | 0.8×-0.5× | 0.9×-0.7× | 1.1×-0.6× | 1.2×-0.4× | 1.4×-0.5× | |
| Price / book | 1×-0.6× | 1.2×-1.0× | 1.4×-0.9× | 1.6×-0.8× | 1.9×-1.0× | |
| EV / EBITDA | 11.4×+0.7× | 13.6×+1.5× | 13.3×+0.8× | 11.1×-3.3× | 11.7×-5.9× | |
| EV / sales | 1.4×-0.5× | 1.5×-0.8× | 1.7×-0.7× | 1.9×-0.5× | 2.1×-0.6× | |
| Free cash flow yield | 11.9%+1.7pp | 12%+4.7pp | 10.2%+2.7pp | 9.1%+1.6pp | 8.8%+3.1pp | |
| Earnings yield | 5.3%-2.1pp | 3.7%-2.5pp | 4.4%-1.5pp | 6.7%+2.1pp | 6.4%+3.0pp | |
| Dividend yield | 1.8%+0.3pp | 2%+0.8pp | 1.7%+0.6pp | 1.5%+0.4pp | 1.3%+0.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CONMED's profit margins?
- CONMED (CNMD) runs a 55.2% gross margin and a 8.2% operating margin, with a 4.0% net margin.
- Where do CONMED's ratios come from?
- Every ratio is computed from CONMED's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
